PRKAA1 and ovarian cancer: On the other hand, upon treatment with 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a potent and direct AMPK activator25, we demonstrated that increased AMPK inversely correlated with TAK1 activity of ovarian cancer cells in a dose-dependent manner of PF-06409577 (Fig. 5d).